Free Trial

argenx (ARGX) Stock Forecast & Price Target

argenx logo
$584.95 +6.64 (+1.15%)
Closing price 04:00 PM Eastern
Extended Trading
$584.45 -0.50 (-0.09%)
As of 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
22

Based on 23 Wall Street analysts who have issued ratings for argenx in the last 12 months, the stock has a consensus rating of "Buy." Out of the 23 analysts, 1 has given a hold rating, 20 have given a buy rating, and 2 have given a strong buy rating for ARGX.

Consensus Price Target

$698.11
19.35% Upside
According to the 23 analysts' twelve-month price targets for argenx, the average price target is $698.11. The highest price target for ARGX is $1,065.00, while the lowest price target for ARGX is $500.00. The average price target represents a forecasted upside of 19.35% from the current price of $584.95.
Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenx and its competitors.

Sign Up

ARGX Analyst Ratings Over Time

TypeCurrent Forecast
5/21/24 to 5/21/25
1 Month Ago
4/21/24 to 4/21/25
3 Months Ago
2/21/24 to 2/20/25
1 Year Ago
5/22/23 to 5/21/24
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
20 Buy rating(s)
19 Buy rating(s)
18 Buy rating(s)
14 Buy rating(s)
Hold
1 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$698.11$699.28$658.39$524.68
Forecasted Upside19.35% Upside17.39% Upside1.68% Upside47.11% Upside
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Moderate Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

argenx Stock vs. The Competition

TypeargenxMedical CompaniesS&P 500
Consensus Rating Score
3.04
2.81
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside19.35% Upside4,200.64% Upside15.76% Upside
News Sentiment Rating
Positive News

See Recent ARGX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/14/2025JMP Securities
2 of 5 stars
Jason Butler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$699.00+30.93%
5/14/2025Citigroup
3 of 5 stars
 Reiterated RatingOutperform ➝ Outperform
5/13/2025Baird R W
0 of 5 stars
J. Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/13/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joel Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$680.00 ➝ $680.00+21.23%
5/9/2025Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Leland Gershell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$704.00 ➝ $708.00+27.59%
5/9/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Yatin Suneja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$1,100.00 ➝ $1,065.00+94.38%
4/11/2025Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00 ➝ $715.00+23.83%
4/8/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Douglas Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00 ➝ $720.00+31.16%
3/17/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/12/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
2/28/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Derek Archila
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$723.00 ➝ $741.00+19.70%
2/28/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/14/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joon Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$660.00 ➝ $700.00+3.93%
1/7/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$620.00 ➝ $725.00+12.34%
11/21/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$675.00 ➝ $706.00+19.29%
11/12/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$697.00+18.35%
11/5/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Farmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Sector Outperform$439.00 ➝ $715.00+21.46%
11/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$640.00 ➝ $670.00+12.61%
10/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy$605.00+16.23%
8/6/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Pitman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight
6/24/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$535.00 ➝ $607.00+40.57%
6/24/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$485.00 ➝ $500.00+14.82%
5/28/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$515.00 ➝ $510.00+39.29%
12/12/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$612.00 ➝ $641.00+41.35%
10/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$605.00 ➝ $628.00+29.56%
7/24/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$480.00 ➝ $570.00+3.93%
6/15/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:10 PM ET.


Should I Buy argenx Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 19, 2025. Please send any questions or comments about these argenx pros and cons to contact@marketbeat.com.

argenx
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in argenx SE:

  • The current stock price is around $563, which may present a buying opportunity for investors looking for growth in the biotech sector.
  • Recent upgrades from analysts, including a shift to an "outperform" rating, indicate positive sentiment and potential for stock appreciation.
  • Institutional ownership stands at over 60%, suggesting confidence from major investors in the company's future performance.
  • Multiple analysts have set price targets significantly above the current stock price, indicating potential upside for investors.
  • Recent acquisitions by institutional investors, such as Fred Alger Management LLC, reflect growing interest and confidence in argenx SE's prospects.

argenx
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in argenx SE for these reasons:

  • Despite positive analyst ratings, the stock has experienced volatility, with a twelve-month high of $678.21 and a low of $356.38, indicating potential risk.
  • Some analysts have lowered their price targets, which may signal caution regarding the company's near-term performance.
  • The biotech sector can be highly unpredictable, with regulatory challenges and market competition posing risks to argenx SE's growth.
  • Investors should consider the overall market conditions, which can impact stock performance regardless of company fundamentals.
  • While institutional ownership is high, it can also lead to significant sell-offs if major investors decide to exit their positions, potentially impacting stock price negatively.

ARGX Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for argenx is $698.11, with a high forecast of $1,065.00 and a low forecast of $500.00.

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There is currently 1 hold rating, 20 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARGX shares.

According to analysts, argenx's stock has a predicted upside of 19.35% based on their 12-month stock forecasts.

Over the previous 90 days, argenx's stock had 4 upgrades by analysts.

Analysts like argenx more than other "medical" companies. The consensus rating for argenx is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARGX compares to other companies.


This page (NASDAQ:ARGX) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners